Avidity Biosciences, Inc.
Price Action
Technical Summary
EMERGING TRENDAvidity Biosciences, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is weak (RS Rating: 2), showing significant lag compared to the market leaders. Earnings contraction of 99% provides fundamental context to the price action. Investors should exercise caution due to high volatility (109% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $69.91 | -78.90% | BELOW |
| 50 SMA | $71.36 | -79.33% | BELOW |
| 100 SMA | $67.75 | -78.23% | BELOW |
| 150 SMA | $59.70 | -75.30% | BELOW |
| 200 SMA | $52.61 | -71.96% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RNA in an uptrend right now?
RNA has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is RNA overbought or oversold?
RNA's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is RNA outperforming the market?
RNA has a Relative Strength (RS) Rating of 2 out of 99. RNA is currently lagging the broader market.
Where is RNA in its 52-week range?
RNA is trading at $14.75, which is 20% of its 52-week high ($73.06) and 3% above its 52-week low ($13.14).
How volatile is RNA?
RNA has a Beta of 1.08 and 52-week volatility of 109%. It's more volatile than the S&P 500 - expect bigger swings.